Top 5 AJMC® Articles of June 2019

Hi, this is Jaime Rosenberg for The American Journal of Managed Care^®. Here are the top 5 articles for the month of June.

Number 5: The final morning of the American Diabetes Association (ADA) Scientific Sessions featured cardiovascular and renal results from recent trials involving type 2 diabetes drugs, including CREDENCE, the first dedicated renal outcomes trial for a type 2 diabetes therapy.

Number 4: Although multiple cancers are attributable to the human papillomavirus, or HPV, uptake of the vaccine remains low 13 years after it was first introduced. Among the populations that should be vaccinated in the United States, only 49% actually receive the vaccine.

Number 3: During ASCO’s annual meeting, the organization held a town hall to discuss the topic of drug pricing, which brought tense conversation about the subject.

Number 2: An analysis of phase 3 trial data for investigational type 2 diabetes drug oral semaglutide showed that GLP-1 receptor agonist does a better job reducing blood sugar than leading SGLT2 inhibitor empagliflozin.

Number 1: Findings from ADA showed that the type 2 diabetes drug dapagliflozin significantly reduced the risk of renal decline, kidney failure, and renal death.

To read all of these articles and more, visit ajmc.com.